Market Overview

Benzinga's Top #PreMarket Losers

Related TRGT
Catalyst Biosciences Announces Positive Results From a Phase 1 Clinical Trial of Its Next Generation Coagulation Factor VIIa in Patients With Hemophilia A or B and Preclinical Results
Targacept and Catalyst Biosciences Amend Definitive Merger Agreement
Related RMTI
Watch These 5 Huge Put Purchases In Friday Trade
Benzinga's Option Alert Recap From September 14

Targacept (NASDAQ: TRGT) shares fell 31.93% to $4.05 in the pre-market trading after the company announced negative top-line results from Phase 2b clinical trial of TC-5619 in Schizophrenia.

Rockwell Medical (NASDAQ: RMTI) dipped 12.03% to $11.85. Brean Capital initiated coverage on the stock with a Sell rating.

Expedia (NASDAQ: EXPE) dipped 7.47% to $60.96 in the pre-market session. Expedia's trailing-twelve-month profit margin is 3.15%.

Fiserv (NASDAQ: FISV) shares dropped 3.21% to $54.87 in pre-market trading. Fiserv's PEG ratio is 2.67.

Posted-In: PreMarket LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (EXPE + FISV)

View Comments and Join the Discussion!

Partner Center